Clinical Study to Assess Efficacy and Safety of LN-145 (Autologous Centrally Manufactured Tumor Infiltrating Lymphocytes) Across Multiple Tumor Types
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 23 Mar 2018
At a glance
- Drugs LN 145 (Primary) ; Cyclophosphamide; Fludarabine; Mesna
- Indications Cervical cancer; Osteosarcoma; Ovarian cancer; Soft tissue sarcoma
- Focus Therapeutic Use
- Acronyms Iovance Alliance
- 19 Mar 2018 Planned End Date changed from 1 Dec 2021 to 1 Jun 2022.
- 19 Mar 2018 Planned primary completion date changed from 1 Dec 2020 to 1 Jun 2021.
- 27 Jun 2017 According to an Iovance Biotherapeutics media release, Lion Biotechnologies has changed its name to Iovance Biotherapeutics.